Project start: 24/07/2023

Project end: 12/01/2024

Researchers from the AWRC and BMRC have carried out a randomised double-blind placebo-controlled trial of a multi-strain liquid probiotic in 196 people with Long COVID.

Studies have shown that COVID-19 alters the gut microbiome composition, leading to a reduction in beneficial bacteria and an increase in pathogenic bacteria. This may contribute to the symptoms of Long COVID, including fatigue, brain dysfunction, and gastrointestinal issues. Some probiotic strains are known to have immune-modulating effects, potentially reducing the hyperinflammatory state seen in Long COVID.

Participants were provided with a flavoured drink to take each day for 12 weeks. For half the group the drink contained four strains of beneficial probiotics, the other half had an identical drink but without the probiotics. Everyone filled in questionnaires about their symptoms before the start of the study, and at 4, 8 and 12 weeks, and used an app for 3 weeks at the start and end of the study to track their symptoms. A third of the participants came into the laboratory at the start and end of the study to carry out a cognitive function test and give a blood sample to test for inflammatory markers. This group also wore an activity tracker to measure their movement and sleep.

The research team are currently analysing the results of the study and will share their findings in the next few months.